Dimitrios Z.
- Country
- Greece
- Department
- 1 st Department of Pediatrics of AUTh
Research Overview
- Phase 3 Open-Label Extension Study on Viltolarsen Safety and Efficacy in Ambulatory Male Patients with Duchenne Muscular Dystrophy
- A phase 3, prospective, open-label, multisite, extension of phase 3 studies to assess the long-term safety and tolerability of soticlestat as adjunctive therapy in subjects with Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
Data & Insights
Has run more than one trial at 1 of 41 partner sites.
Specializations
Neuromuscular Disorders
The investigator specializes in studying therapeutic approaches for Duchenne Muscular Dystrophy (DMD), focusing on innovative treatment strategies through intravenous administration methods.
- Muscular dystrophy management
- Progressive muscle weakness treatment
- Neuromuscular disorder interventions
Their research encompasses evaluating novel therapeutic agents for improving patient outcomes in DMD.
Epilepsy Syndromes
The investigator focuses on treating complex epileptic conditions, particularly Dravet Syndrome and Lennox-Gastaut Syndrome, exploring adjunctive therapy approaches.
- Refractory epilepsy treatment
- Combination therapy strategies
- Long-term epilepsy management
Their work includes evaluation of treatments alongside standard of care options including antiseizure medications and dietary interventions.
Therapeutic Applications
The investigator's expertise extends to developing long-term treatment protocols and studying adjunctive therapeutic approaches for rare neurological conditions.
- Safety and tolerability assessment
- Chronic disease management
- Integration of multiple treatment modalities
Their research encompasses comprehensive evaluation of therapeutic interventions in challenging neurological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.